GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MedPacto 235980.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

3,550

+6.29%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩3.90bn

FY2017FY2025

Net income

−₩12.81bn

FY2017FY2025

Free cash flow

−₩13.63bn

FY2017FY2025

Shareholders' equity

₩45.98bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₩3.90bn————————
Gross profit₩385.2m————————
Research and development₩10.14bn₩18.02bn₩24.16bn₩31.92bn₩24.55bn₩23.96bn———
Operating income−₩14.02bn−₩21.82bn−₩35.36bn−₩37.19bn−₩29.46bn−₩27.80bn−₩13.24bn−₩10.16bn−₩3.23bn
Net income−₩12.81bn−₩20.14bn−₩35.32bn−₩35.75bn−₩17.04bn−₩25.35bn−₩13.52bn−₩37.58bn−₩3.47bn
Diluted earnings per share-373.76-587.61-1,051.94-1,487.92-728.64-1,246.24-669.26-2,415.49-339.57

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₩48.66bn₩60.79bn₩80.47bn₩107.69bn₩133.35bn₩58.50bn₩80.70bn₩31.82bn₩1.33bn
Cash and short-term investments—₩55.48bn₩72.60bn₩96.95bn₩121.57bn₩45.30bn₩72.36bn₩29.86bn₩229.0m
Total liabilities₩2.68bn₩3.04bn₩9.57bn₩75.36bn₩89.80bn₩2.75bn₩2.00bn₩27.24bn₩11.63bn
Debt—₩460.8m₩6.92bn₩67.13bn₩75.60bn₩599.0m₩799.0m₩1.95bn₩4.38bn
Shareholders' equity₩45.98bn₩57.74bn₩70.91bn₩32.32bn₩43.54bn₩55.74bn₩78.69bn₩4.58bn−₩10.29bn
Shares outstanding34m34m34m24m23m20m20m16m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−₩13.39bn−₩16.56bn−₩26.30bn−₩29.61bn−₩25.15bn−₩23.38bn−₩15.20bn−₩8.12bn−₩2.69bn
Capital spending−₩243.1m−₩322.7m−₩172.9m−₩877.6m−₩756.6m−₩718.1m−₩2.58bn−₩754.5m−₩81.4m
Free cash flow−₩13.63bn−₩16.88bn−₩26.47bn−₩30.49bn−₩25.91bn−₩24.10bn−₩17.79bn−₩8.88bn−₩2.77bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩1.05bn₩1.32bn₩1.43bn₩1.20bn₩839.6m₩429.9m——
Gross profit₩58.5m₩91.2m₩165.1m₩102.0m₩177.9m−₩59.9m——
Operating income−₩3.58bn−₩4.17bn−₩2.92bn−₩4.74bn−₩2.56bn−₩3.65bn−₩4.80bn−₩2.20bn
Net income−₩3.19bn−₩3.76bn−₩2.67bn−₩4.52bn−₩2.27bn−₩3.36bn−₩4.43bn−₩1.75bn
Diluted earnings per share-93.18-109.70-77.77-131.87-66.13-97.99-129.12-52.22
Cash from operations−₩2.27bn−₩2.93bn−₩2.46bn−₩4.51bn−₩3.02bn−₩3.40bn−₩16.56bn−₩13.84bn
Capital spending−₩22.0m−₩63.0m−₩96.0m−₩58.0m−₩37.0m−₩50.0m−₩322.0m−₩70.0m
Free cash flow−₩2.30bn−₩3.00bn−₩2.55bn−₩4.57bn−₩3.05bn−₩3.45bn−₩16.88bn−₩13.91bn
Total assets₩42.27bn₩45.36bn₩48.66bn₩51.58bn₩55.47bn₩55.76bn₩60.79bn₩66.25bn
Cash and short-term investments—————₩51.63bn₩55.48bn₩58.49bn
Shareholders' equity₩39.50bn₩42.58bn₩45.98bn₩48.39bn₩52.43bn₩54.64bn₩57.74bn₩56.22bn

Financial ratios

Data as of 5 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin9.9%——————
Operating margin-359.6%——————
Net margin-328.6%——————
Return on equity-27.9%-34.9%-49.8%-110.6%-39.1%-45.5%—
Return on assets-26.3%-33.1%-43.9%-33.2%-12.8%-43.3%—
Earnings growth-36.4%-43.0%-1.2%109.8%-32.8%87.6%—
Current ratio32.86x41.29x9.71x1.51x128.95x19.90x—
Debt to equity—0.00x0.00x0.07x1.73x0.00x0.00x
Equity ratio94.5%95.0%88.1%30.0%32.7%95.3%—
Interest coverage-119.50x-237.29x-71.69x-3.87x-3.79x-888.98x—
R&D as a share of sales260.0%——————

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-27.8%-12.8%—
Net income-29.0%-12.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-17.9-7.5-6.9-12.8-68.7-80.6-28.2
Price to sales58.7——————

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 13 May 2020

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.